Clinical Trial Update: A Study to Evaluate the Efficacy After Allergen Challenge, Safety and Tolerability of Inhaled CHF6001 DPI in Asthmatics [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the efficacy after allergen challenge, safety, and tolerability of inhaled CHF6001 dry powder inhaler in asthmatics has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• CHF6001

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Asthma | Phase 2 | Status: COMPLETED